INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 130 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 2.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $358,218 | +131.1% | 26,673 | +137.8% | 0.12% | +51.9% |
| Q2 2022 | $155,000 | -52.5% | 11,216 | +173.6% | 0.08% | -64.5% |
| Q2 2019 | $326,000 | -71.8% | 4,099 | -79.3% | 0.22% | -35.8% |
| Q4 2017 | $1,156,000 | +123.6% | 19,786 | +122.3% | 0.34% | +131.5% |
| Q3 2017 | $517,000 | -28.8% | 8,900 | +48.3% | 0.15% | -41.8% |
| Q2 2017 | $726,000 | +64.6% | 6,000 | +53.8% | 0.25% | +39.4% |
| Q1 2017 | $441,000 | – | 3,900 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |